Back to Search Start Over

PAIN trial: phase II, single-center, double-blinded RCT comparing the efficacy of high dose of liposomal bupivacaine and standard bupivacaine periarticular injection in relieving immediate postoperative pain after total knee arthroplasty. Study protocol

Authors :
Chile. Clínica Alemana de Santiago. Santiago
Rayyan Abdulaziz Attya Fadel
Rand A. Alattar
Winnie Mathur
Murillo Macedo Lobo Filho
Nervana Elbakary
Fernanda Cruvinel de Abreu
Ronan Jose Vieira Neto
Maham Zahid
Fabiana Patricia Morosini Perez
Luis Jesús López Aboytes
Mohak Bariatrics
Laura A. Downey
Felix Hofmann
Gustavo Costa Baumgratz Lopes
Tristan Mirko Struja
Daniel Silva Nogueira
Thiago Artioli
Juan Sebastian Vargas Hernandez
Uruguay. Centro Hospitalario Pereira Rossell. Montevideo
Pablo Ignacio Carreno Montenegro
Daniela Goyes
Salma Elnour Mohamed
Jessica Monteiro Machado
Heba Jamaluddin Mominkhan
Ahmed K.J Elnajjar
Maria Julia Minetto
Nadeem Asghar Cheema
Atamai Caetano Moraes
Jael Garrido Dominguez
Roberta Rossi Grudtner
Colombia. Fundacíon Clínica Shaio. Bogota
Federico Javier Nunez Ricardo
Faissal Nemer Hajar
Cesar Caverzan
Source :
Principles and Practice of Clinical Research Journal. 6:6-12
Publication Year :
2020
Publisher :
Principles and Practice of Clinical Research, 2020.

Abstract

Introduction: Anesthetic strategies to improve postoperative pain management after Total Knee Arthroplasty (TKA) include multimodal pain management to minimize opiate requirements. Postoperatively, subcutaneous standard bupivacaine HCl is often used. Recent studies have suggested that high dose liposomal bupivacaine may result in improved outcomes. Objectives: This study aims to compare periarticular injection of 399mg (high dose) Liposomal Bupivacaine to Standard Bupivacaine in patients undergoing Total Knee Arthroplasty. Methods: We propose a phase II, single-institution, randomized, controlled, double-blinded, superiority trial with two parallel arms with a 1:1 allocation ratio. The two arms of the study will be standard bupivacaine and liposomal bupivacaine at 399mg dose. We will include patients with age >50 years, with primary knee osteoarthritis requiring TKA, ASA status 1 and 2, without opioid consumption in the last 3 months, and with signed informed consent. Exclusion criteria are history of substance abuse, uncontrolled psychiatric disorder, hepatic cirrhosis, renal failure, rheumatoid arthritis, immune arthritis, post-traumatic osteoarthritis, active malignancy or oncologic disease, pregnancy, synchronic surgical intervention, and morbid obesity with Body Mass Index (BMI) equal or greater than 40kg/m2. The primary outcome is time to first opioid rescue. Secondary outcomes include total opioid consumption, VAS scale, adverse events, GROC score, arc of motion, bupivacaine serum levels, length of stay, and mobilization. Discussion: Improving total knee arthroplasty postoperative pain without opioids decreases opioid-related side effects, reduces costs, and improves outcomes. By decreasing opiate use and complications related to them, Liposomal Bupivacaine may improve patient satisfaction as well as functional outcomes.

Details

ISSN :
23781890
Volume :
6
Database :
OpenAIRE
Journal :
Principles and Practice of Clinical Research Journal
Accession number :
edsair.doi...........ac538eaeddfeafb884ce0cbc76eafd80
Full Text :
https://doi.org/10.21801/ppcrj.2020.62.2